EGb 761® (Standardized Ginkgo biloba Extract — Dr. Willmar Schwabe)
EGb 761® is a standardized ginkgo leaf extract originated by Dr. Willmar Schwabe and sold in Europe as Tebonin® and, through Ipsen, as Tanakan®. It contains about 24% flavone glycosides and 6% terpene lactones, and it is the extract used in most large ginkgo trials. In the EU, ginkgo leaf extracts of this type are regulated as herbal medicines, and the European Medicines Agency recognizes well-established use for age-associated cognitive impairment and quality of life in mild dementia. The evidence splits by who takes it. In people already diagnosed with dementia, trials of 240 mg a day over 22 to 26 weeks reported better cognition, behavior and daily function; the 2026 Cochrane review rated the gains in cognition and daily activities small to moderate and low certainty. In older adults without dementia (some with memory complaints or mild cognitive impairment), two large trials of about 3,000 people each found it did not lower the number who developed dementia, and one found no slowing of memory or thinking decline over about 6 years. Ginkgo may raise bleeding risk, so do not combine it with blood thinners without medical advice.
Benefits
Cognition and daily function
In people already diagnosed with dementia, 240 mg a day improved cognition, daily function and global ratings versus placebo over 22 to 26 weeks, and meta-analyses of those trials report benefits, but the latest review, of 82 trials, rated the dementia gains small to moderate and low certainty and found probably little or no effect in mild cognitive impairment. In older adults without dementia, large trials found no slowing of decline.
Mood, apathy and irritability
In two trials of 22 and 24 weeks with about 810 people who had dementia and marked behavioral symptoms, 240 mg a day improved Neuropsychiatric Inventory scores, which cover apathy, anxiety, irritability and low mood, more than placebo. In the 24-week trial the score improved by 4.6 points versus 2.1. These results come from people with dementia, not healthy adults.
Anxiety and tension
In one 4-week trial of 107 people diagnosed with generalized anxiety disorder or adjustment disorder with anxious mood, Hamilton Anxiety scores fell by 14.3 points on 480 mg a day and 12.1 points on 240 mg, versus 7.8 on placebo. This is a single short trial in diagnosed patients and is not a reason to stop or replace prescribed care.
Blood flow and circulation
Ginkgolides block platelet-activating factor, and the flavonoids neutralize free radicals in laboratory studies. In people, a Cochrane review of 14 trials (739 people) with leg pain on walking found no clinically significant gain in walking distance, and over 5 years strokes were similar on ginkgo and placebo (65 vs 60).
Mechanism of action
Platelet-Activating Factor Inhibition & Microcirculation
Ginkgolides, particularly ginkgolide B, antagonize platelet-activating factor (PAF), and in laboratory studies reduce platelet aggregation and blood viscosity and promote nitric-oxide-mediated vasodilation. These are pharmacology findings, not measured clinical benefits: randomized trials in intermittent claudication found no clinically significant gain in walking distance. The same platelet-activating-factor effect is why ginkgo carries a bleeding-interaction warning.
Antioxidant / Free-Radical Scavenging
In laboratory studies the flavonol glycosides (quercetin, kaempferol, isorhamnetin) scavenge reactive oxygen species and bind pro-oxidant metals, protecting nerve and blood vessel cells from oxidative stress.
Neuroprotection & Mitochondrial Stabilization
In laboratory studies bilobalide stabilizes mitochondrial membranes, supports energy production and may limit nerve cell damage when oxygen supply is low.
Neurotransmitter Modulation
In laboratory studies the extract influences acetylcholine, serotonin and dopamine signaling and may mildly inhibit monoamine oxidase. How much these effects explain the trial results in people is not known.
Clinical trials
Placebo-controlled double-blind randomized trial of EGb 761 120 mg a day for 52 weeks in outpatients with mild to severe Alzheimer's disease or multi-infarct dementia (North American EGb Study Group). (Le Bars et al. 1997, JAMA)
309 patients with Alzheimer's or multi-infarct dementia. 52-week intervention.
EGb 761 was 1.4 points better than placebo on the ADAS-Cog (P=0.04) and 0.14 points better on the caregiver-rated GERRI (P=0.004); clinician global impression did not differ. 27% versus 14% improved by at least 4 ADAS-Cog points. Only 202 of the 309 patients provided evaluable data at 52 weeks.
Ginkgo Evaluation of Memory Study: randomized double-blind placebo-controlled trial of EGb 761 120 mg twice daily (registry NCT00010803), median follow-up 6.1 years. (DeKosky et al. 2008, JAMA)
3,069 community volunteers aged 75 or older with normal cognition (2,587) or mild cognitive impairment (482).
Dementia developed in 277 people on ginkgo and 246 on placebo: hazard ratio 1.12 for all-cause dementia (P=0.21) and 1.16 for Alzheimer's disease (P=0.11), neither significant. Ginkgo also did not slow progression to dementia in those with mild cognitive impairment. A later report from this cohort found no slowing of decline in any thinking domain.
Randomized double-blind placebo-controlled trial of EGb 761 120 mg twice daily for 5 years, funded by Ipsen. (Vellas et al. 2012, Lancet Neurol)
2,854 adults aged 70 or older who had reported memory complaints to their doctor.
Probable Alzheimer's disease was diagnosed in 61 people on ginkgo and 73 on placebo (hazard ratio 0.84, P=0.306), not a significant difference. Deaths (76 vs 82), strokes (65 vs 60) and other bleeding or cardiovascular events did not differ.
24-week multicenter randomized double-blind placebo-controlled trial of EGb 761 240 mg once daily. (Herrschaft et al. 2012, J Psychiatr Res)
410 outpatients with mild to moderate Alzheimer's or vascular dementia and neuropsychiatric symptoms.
The SKT cognitive score improved by 2.2 points on EGb 761 versus 0.3 on placebo, and the NPI behavioral score by 4.6 versus 2.1 (both P<0.001). Most secondary measures, including daily function and quality of life, also favored EGb 761.
Systematic review and meta-analysis of 9 placebo-controlled randomized trials of EGb 761 lasting 22 to 26 weeks, with 2,561 patients in total. (Tan et al. 2015, J Alzheimers Dis)
People with cognitive impairment or dementia across 9 trials.
Cognition, activities of daily living and clinician global rating all favored EGb 761 over placebo, mainly at 240 mg a day, with no important safety concerns. In people with neuropsychiatric symptoms the benefit was larger, while results in the Alzheimer's disease subgroup were much the same as in the whole group.
Side effects and drug interactions
Common Potential side effects
Important Drug interactions
Frequently asked questions about EGb 761® (Standardized Ginkgo biloba Extract — Dr. Willmar Schwabe)
What is EGb 761?
EGb 761® is a standardized ginkgo leaf extract originated by Dr. Willmar Schwabe and sold in Europe as Tebonin® and, through Ipsen, as Tanakan®. It contains about 24% flavone glycosides and 6% terpene lactones, and it is the extract used in most large ginkgo trials.
What is EGb 761 used for?
EGb 761 is researched primarily for Cognitive and Mood & Mental Health. In people already diagnosed with dementia, 240 mg a day improved cognition, daily function and global ratings versus placebo over 22 to 26 weeks, and meta-analyses of those trials report benefits, but the latest review, of 82 trials, rated…
What is the recommended dosage of EGb 761?
The clinically studied dose is 240 mg/day in the dementia and prevention trials, taken once daily or as 120 mg twice daily; 120 mg/day in Le Bars 1997. The anxiety trial used 240 and 480 mg/day. Always follow the product label and check with a healthcare provider for personal advice.
Is EGb 761 safe, and does it have side effects?
Side effects and cautions reported for EGb 761 include: Gastrointestinal upset: nausea, stomach discomfort, or diarrhea. Headache (listed as very common in the EU herbal monograph), dizziness and digestive upset (common). It may also interact with some medications. EGb 761 is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.
Does EGb 761 interact with any medications?
Possible interactions include: Anticoagulants/antiplatelets (warfarin, aspirin, clopidogrel): additive bleeding risk via platelet-activating-factor inhibition; monitor closely. Antidepressants: no human interaction study found; a PET study found EGb 761 did not inhibit monoamine oxidase in the human brain. If you take prescription medication, check with a pharmacist or doctor before using it.
How strong is the scientific evidence for EGb 761?
NutraSmarts rates the evidence for EGb 761 as Moderate (3 out of 5). It is backed by 5 study summaries and 18 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.
References(18 citations)
Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.
- A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group. JAMA. 1997;278(16):1327-32. doi: 10.1001/jama.278.16.1327.PubMedUsed to support: The influential early positive trial. Over 52 weeks in Alzheimer's/multi-infarct dementia, EGb 761 120 mg/day produced a small but statistically significant benefit versus placebo on ADAS-Cog and caregiver-rated GERRI; established EGb 761 as the reference ginkgo extract.
- Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA. 2008;300(19):2253-62. doi: 10.1001/jama.2008.683.PubMedUsed to support: Negative prevention trial and the largest study of this extract. In 3,069 community-dwelling adults aged 75 or older with normal cognition or mild cognitive impairment, 120 mg twice daily for a median 6.1 years did not reduce dementia: hazard ratio 1.12 for all-cause dementia (95% CI 0.94 to 1.33, p=0.21) and 1.16 for Alzheimer's disease (95% CI 0.97 to 1.39, p=0.11), with 277 cases on ginkgo versus 246 on placebo.
- Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial. Lancet Neurol. 2012;11(10):851-9. doi: 10.1016/S1474-4422(12)70206-5.PubMedUsed to support: Negative prevention trial. In 2,854 adults aged 70 or older who had spontaneously reported memory complaints to their doctor, 120 mg twice daily for 5 years did not reduce progression to probable Alzheimer's disease: 61 cases on ginkgo versus 73 on placebo, hazard ratio 0.84 (95% CI 0.60 to 1.18, p=0.306). Strokes (65 versus 60) and other cardiovascular and haemorrhagic events did not differ. Funded by Ipsen, which markets this extract as Tanakan.
- Ginkgo biloba extract EGb 761® in dementia with neuropsychiatric features: a randomised, placebo-controlled trial to confirm the efficacy and safety of a daily dose of 240 mg. J Psychiatr Res. 2012;46(6):716-23. doi: 10.1016/j.jpsychires.2012.03.003.PubMedUsed to support: 24-week RCT (n=410) in mild to moderate Alzheimer's or vascular dementia with neuropsychiatric symptoms: EGb 761 240 mg a day improved the SKT cognitive score (2.2 vs 0.3 points) and NPI score (4.6 vs 2.1 points) versus placebo, both P<0.001, with most secondary measures also favoring EGb 761.
- Ginkgo biloba special extract in dementia with neuropsychiatric features. A randomised, placebo-controlled, double-blind clinical trial. Arzneimittelforschung. 2007;57(1):4-11. doi: 10.1055/s-0031-1296579.PubMedUsed to support: Positive symptomatic trial. 22-week RCT (n=400) in mild-to-moderate Alzheimer's or vascular dementia with neuropsychiatric features: EGb 761 240 mg/day significantly improved cognition (SKT) and behavioral symptoms (NPI) versus placebo across both dementia subtypes.
- Efficacy and tolerability of Ginkgo biloba extract EGb 761® in dementia: a systematic review and meta-analysis of randomized placebo-controlled trials. Clin Interv Aging. 2014;9:2065-77. doi: 10.2147/CIA.S72728.PubMedUsed to support: Meta-analysis of 7 RCTs (2,625 patients) of 120 or 240 mg a day for 22 to 26 weeks in dementia: cognition, activities of daily living and global rating favored EGb 761 over placebo, with similar tolerability. One author is listed in PubMed as working in the clinical research department of Dr Willmar Schwabe.
- Efficacy and adverse effects of ginkgo biloba for cognitive impairment and dementia: a systematic review and meta-analysis. J Alzheimers Dis. 2015;43(2):589-603. doi: 10.3233/JAD-140837.PubMedUsed to support: Independent meta-analysis of 9 randomized trials, 2,561 patients, all 22 to 26 weeks. Pooled results favoured EGb 761 at 240 mg/day for cognition (weighted mean difference -2.86, 95% CI -3.18 to -2.54), activities of daily living and clinician global impression, with the largest effect in the subgroup who had neuropsychiatric symptoms. In the Alzheimer's-only subgroup the results were about the same as the pooled group with no additional advantage. Independent of the manufacturer, but pooling largely manufacturer-run trials.
- Ginkgo biloba special extract EGb 761 in generalized anxiety disorder and adjustment disorder with anxious mood: a randomized, double-blind, placebo-controlled trial. J Psychiatr Res. 2007;41(6):472-80. doi: 10.1016/j.jpsychires.2006.05.004.PubMedUsed to support: 4-week RCT (n=107) in generalized anxiety disorder or adjustment disorder with anxious mood: Hamilton Anxiety scores fell by 14.3 points on 480 mg a day and 12.1 on 240 mg versus 7.8 on placebo (P=0.0003 and P=0.01), with a dose-response trend.
- Ginkgo biloba for preventing cognitive decline in older adults: a randomized trial. JAMA. 2009;302(24):2663-70. doi: 10.1001/jama.2009.1913.PubMedUsed to support: Cognitive outcomes from the same GEM cohort as DeKosky 2008, not a separate trial. In 3,069 adults aged 72 to 96 followed a median 6.1 years, 120 mg twice daily produced no difference from placebo in the annual rate of decline in memory, attention, visuospatial ability, language or executive function, and no difference on the 3MSE or ADAS-Cog, with no effect modification by age, sex, APOE4 status or baseline mild cognitive impairment.
- Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev. 2009;2009(1):CD003120. doi: 10.1002/14651858.CD003120.pub3.PubMedUsed to support: Cochrane review of 36 randomized double-blind trials of ginkgo in acquired cognitive impairment and dementia. Nine trials of six months' duration covering 2,016 patients were judged adequate in size and quality. The reviewers found no consistent pattern of benefit, including in a subgroup of 925 Alzheimer's patients from nine trials, and concluded that the evidence for a predictable and clinically significant benefit is inconsistent and unreliable. Adverse events did not differ from placebo. This is a systematic review, not a trial.
- Ginkgo biloba for intermittent claudication. Cochrane Database Syst Rev. 2013;2013(6):CD006888. doi: 10.1002/14651858.CD006888.pub3.PubMedUsed to support: Cochrane review of 14 randomized trials in 739 people with intermittent claudication. Pooling the 11 placebo-controlled trials that reported absolute claudication distance, ginkgo increased it by 3.57 kcal (95% CI -0.10 to 7.23, p=0.06), equivalent to about 64.5 metres (95% CI -1.8 to 130.7) on a flat treadmill, and the reviewers judged that publication bias had probably inflated even that. Their conclusion was that there is no evidence of clinically significant benefit in peripheral arterial disease. This is a systematic review, not a trial.
- Is there a risk of bleeding associated with standardized Ginkgo biloba extract therapy? A systematic review and meta-analysis. Pharmacotherapy. 2011;31(5):490-502. doi: 10.1592/phco.31.5.490.PubMedUsed to support: Meta-analysis of 18 randomized controlled trials in 1,985 adults, of whom 87 percent had dementia, peripheral artery disease or diabetes. Standardized ginkgo extract lowered blood viscosity but produced no significant change versus placebo in ADP-induced platelet aggregation, fibrinogen, prothrombin time or aPTT; a small aPTT reduction at doses of 240 mg/day or more was judged not clinically relevant. The authors concluded these hemostasis measures do not demonstrate a higher bleeding risk. Bleeding case reports in ginkgo users are a separate line of evidence that this analysis does not address.
- Spontaneous bleeding associated with ginkgo biloba: a case report and systematic review of the literature: a case report and systematic review of the literature. J Gen Intern Med. 2005;20(7):657-61. doi: 10.1111/j.1525-1497.2005.0121.x.PubMedUsed to support: Systematic review of published case reports: 15 reports linked ginkgo use in time to a bleeding event, 8 of them inside the skull, but 13 involved other bleeding risk factors. The authors judged a causal link possible and advised counseling about bleeding risk.
- EGb 761: ginkgo biloba extract, Ginkor. Drugs R D. 2003;4(3):188-93. doi: 10.2165/00126839-200304030-00009.PubMedUsed to support: Drug profile: EGb 761 contains about 24% flavone glycosides and 6% terpene lactones, was originated by Dr Willmar Schwabe, and is developed as Tebonin by Schwabe and as Tanakan by Beaufour-Ipsen.
- European Union herbal monograph on Ginkgo biloba L., folium (EMA/HMPC/321097/2012) European Medicines Agency. 2015;Final, adopted 28 January 2015..SourceUsed to support: Not PubMed-indexed. Well-established use of refined ginkgo leaf dry extract (acetone 60%, DER 35 to 67:1) for the improvement of age-associated cognitive impairment and of quality of life in mild dementia, at 240 mg a day for at least 8 weeks.
- Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev. 2026;2(2):CD013661. doi: 10.1002/14651858.CD013661.pub2.PubMedUsed to support: Current Cochrane systematic review of ginkgo for cognitive impairment and dementia: 82 randomized trials with 10,613 participants (72 with extractable data), of which only four were at low risk of bias in all domains. In mild cognitive impairment (12 trials, 1,913 participants), ginkgo probably has little or no effect at six months on global clinical status, cognition or daily activities (moderate certainty). In people with subjective memory complaints the effect on global status is uncertain, and one three-month trial found adverse events may be more common with ginkgo. In multiple sclerosis with cognitive problems (2 trials), ginkgo probably has little or no effect on cognition. In people with dementia (13 trials, 3,288 participants), low-certainty evidence suggests small to moderate six-month benefits on global status, cognition (Syndrom-Kurztest) and daily activities, with very high heterogeneity between trials (I squared 88 to 96 percent). Serious adverse events did not differ from placebo.
- Effect of Ginkgo biloba special extract EGb 761® on human cytochrome P450 activity: a cocktail interaction study in healthy volunteers. Eur J Clin Pharmacol. 2012;68(5):553-60. doi: 10.1007/s00228-011-1174-5.PubMedUsed to support: Open-label, randomized, three-way crossover cocktail study in 18 healthy men and women given placebo, EGb 761 120 mg twice daily or 240 mg once daily for 8 days each. Ratios for caffeine (CYP1A2), tolbutamide (CYP2C9), omeprazole (CYP2C19), dextromethorphan (CYP2D6) and midazolam (CYP3A) were close to 1, and the authors concluded EGb 761 has no relevant effect on the major CYP enzymes in people.
- Evidence that gingko biloba extract does not inhibit MAO A and B in living human brain. Life Sci. 2000;66(9):PL141-6. doi: 10.1016/s0024-3205(99)00660-8.PubMedUsed to support: Brain imaging study in 10 people who took 120 mg per day of the EGb 761 extract for one month, using PET scanning with two radiotracers to measure the activity of monoamine oxidase A and monoamine oxidase B directly in the living human brain. Neither enzyme was inhibited. The authors note that ginkgo extracts had been reported to inhibit both enzymes in rat brain in vitro, leading to speculation that this contributes to its effects on the brain, and conclude that other mechanisms need to be considered. The study covered 10 people at one dose for one month.